title: Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier.
abstract: 6-mercaptopurine (6-MP) has been used clinically for 40 years to maintain remission in patients with acute lymphoblastic leukemia (ALL). However, central nervous system (CNS) relapses frequently occur in patients with ALL who continuously receive anticancer drugs, including 6-MP, during remission maintenance therapy. The cause of such CNS relapse is not well understood. One possible reason may involve the restricted distribution of 6-MP in the brain. This study, therefore, investigates the blood-brain barrier (BBB) transport which largely regulates 6-MP distribution in the brain using a quantitative microdialysis technique and centers on the efflux transport of 6-MP across the BBB. The brain tissue, cerebrospinal fluid (CSF), or hippocampal interstitial fluid (ISF) concentration of 6-MP was very low compared with the unbound plasma concentration, suggesting that 6-MP distribution in the brain is highly restricted. Kinetic analyses of this BBB transport showed that the efflux clearance from brain ISF to plasma across the BBB (CLout) is approximately 20-times greater than the influx clearance from plasma to brain (CLin). The CLout was significantly reduced by 1mM N-ethylmaleimide (NEM), a sulfhydryl-modifying agent, suggesting the participation of transport protein in the efflux of 6-MP across the BBB. In addition, efflux transport was inhibited by an intracerebral infusion of probenecid (1.5 mM), p-aminohippuric acid (PAH, 3.0 mM), benzoate (3.6 mM), or salicylate (3.7 mM) administered through a microdialysis probe, but neither choline (0.8 mM) nor tetraethylammonium (TEA, 0.7 mM) had any effect. These data suggest that the restricted 6-MP brain distribution may be ascribed to efficient efflux from the brain, possibly via both the organic anion transport system, shared with probenecid and PAH, and the monocarboxylic acid transport system, shared with benzoate and salicylate.
authors.affiliation: Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Japan. deguchi@ys7.u-shizuoka-ken.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Deguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: T
authors.initials: T
authors.lastname: Sakamoto
authors.forename: H
authors.initials: H
authors.lastname: Hayashi
authors.forename: T
authors.initials: T
authors.lastname: Naito
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: R
authors.initials: R
authors.lastname: Kimura
mesh_terms: D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D005033:Ethylmaleimide / Q000494:pharmacology; D008297:Male; D015122:Mercaptopurine / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate; D017551:Microdialysis; D011339:Probenecid / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001798:Blood Proteins; D015122:Mercaptopurine; D005033:Ethylmaleimide; D011339:Probenecid